CureZone   Log On   Join
Alunbrig: A kinase inhibitor
rajupharma Views: 55
Published: 9 months ago

Alunbrig: A kinase inhibitor

Healthcare professionals recommend using the drug Brigatinib to treat patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC). Alunbrig is the trade name of the drug Bringatinib. Bringatinib is a tyrosine kinase inhibitor with in vitro activity at clinically achievable concentrations against multiple kinases, including ALK, ROS1, insulin-like growth factor-1 receptor (IGF-1R), and FLT-3, well as EGFR deletion and point mutations. Alunbrig tablets come in the strengths of 180 mg, 90 mg and 30 mg for oral administration. The active ingredient in the tablets is Brigatinib, with inactive ingredients lactose monohydrate, microcrystalline cellulose, sodium starch glycolate (Type A), magnesium stearate, and hydrophobic colloidal silica.
Alunbrig price is reasonable, and one can find this medicine from certified generic medicine suppliers. For further information about this medicine, contact us on toll-free no. 18008891064.

Printer-friendly version of this page Email this message to a friend
Alert Moderators
Report Spam or bad message  Alert Moderators on This GOOD Message

This Forum message belongs to a larger discussion thread. See the complete thread below. You can reply to this message!


Donate to CureZone

CureZone Newsletter is distributed in partnership with

Contact Us - Advertise - Stats

Copyright 1999 - 2023

1.000 sec, (1)